Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.

Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, Percival MM, Becker PS, Scott BL, Oehler VG, Gernsheimer TB, Keel SB, Orozco JJ, Cassaday RD, Shustov AR, Hartley GA, Welch VL, Estey EH, Walter RB.

Leukemia. 2019 Oct 4. doi: 10.1038/s41375-019-0586-6. [Epub ahead of print] No abstract available.

PMID:
31586148
2.

The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis.

Godavarthy PS, Kumar R, Herkt SC, Pereira RS, Hayduk N, Weissenberger ES, Aggoune D, Manavski Y, Lucas T, Pan KT, Voutsinas JM, Wu Q, Müller MC, Saussele S, Oellerich T, Oehler VG, Lausen J, Krause DS.

Haematologica. 2019 Apr 24. pii: haematol.2018.212365. doi: 10.3324/haematol.2018.212365. [Epub ahead of print]

3.

The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.

Hoang VT, Verma D, Godavarthy PS, Llavona P, Steiner M, Gerlach K, Michels BE, Bohnenberger H, Wachter A, Oellerich T, Müller-Kuller U, Weissenberger E, Voutsinas JM, Oehler VG, Farin HF, Zörnig M, Krause DS.

Leukemia. 2019 Jul;33(7):1700-1712. doi: 10.1038/s41375-018-0358-8. Epub 2019 Jan 11.

PMID:
30635626
4.

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB.

Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8. No abstract available.

5.

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.

Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA.

Am J Hematol. 2018 Nov;93(11):1301-1310. doi: 10.1002/ajh.25238. Epub 2018 Sep 9.

6.

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.

Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE.

BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1.

7.

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.

Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE.

Clin Cancer Res. 2018 May 15;24(10):2294-2303. doi: 10.1158/1078-0432.CCR-17-2824. Epub 2018 Feb 20.

8.

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.

Lee SI, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Oehler VG, Estey EH, Miller CP, Chien S, Dai J, Saxena A, Blau CA, Becker PS.

Nat Commun. 2018 Jan 3;9(1):42. doi: 10.1038/s41467-017-02465-5.

9.

CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.

Bajaj J, Konuma T, Lytle NK, Kwon HY, Ablack JN, Cantor JM, Rizzieri D, Chuah C, Oehler VG, Broome EH, Ball ED, van der Horst EH, Ginsberg MH, Reya T.

Cancer Cell. 2016 Nov 14;30(5):792-805. doi: 10.1016/j.ccell.2016.10.003. Epub 2016 Oct 27.

10.

miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.

Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, Meshinchi S.

Pediatr Blood Cancer. 2016 Dec;63(12):2096-2103. doi: 10.1002/pbc.26157. Epub 2016 Aug 11.

11.

Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia.

Brehme M, Koschmieder S, Montazeri M, Copland M, Oehler VG, Radich JP, Brümmendorf TH, Schuppert A.

Sci Rep. 2016 Apr 6;6:24057. doi: 10.1038/srep24057.

12.

Small, abnormal B lymphoid blast populations in chronic myelogenous leukemia at diagnosis: Does this finding indicate an accelerated course?

Soma L, Oehler VG, Ding C, Cherian S.

Cytometry B Clin Cytom. 2016 Sep;90(5):440-8. doi: 10.1002/cyto.b.21357. Epub 2016 Mar 11.

13.

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.

Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C.

Lancet Haematol. 2015 Aug;2(8):e339-46. doi: 10.1016/S2352-3026(15)00096-4. Epub 2015 Jul 26.

PMID:
26688487
14.

Deregulated KLF4 Expression in Myeloid Leukemias Alters Cell Proliferation and Differentiation through MicroRNA and Gene Targets.

Morris VA, Cummings CL, Korb B, Boaglio S, Oehler VG.

Mol Cell Biol. 2015 Dec 7;36(4):559-73. doi: 10.1128/MCB.00712-15. Print 2016 Feb 15.

15.

Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia.

Kwon HY, Bajaj J, Ito T, Blevins A, Konuma T, Weeks J, Lytle NK, Koechlein CS, Rizzieri D, Chuah C, Oehler VG, Sasik R, Hardiman G, Reya T.

Cell Stem Cell. 2015 Aug 6;17(2):152-164. doi: 10.1016/j.stem.2015.06.006. Epub 2015 Jul 23.

16.

Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.

Huang JC, Basu SK, Zhao X, Chien S, Fang M, Oehler VG, Appelbaum FR, Becker PS.

Blood Cancer J. 2015 Apr 10;5:e302. doi: 10.1038/bcj.2015.17.

17.

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.

Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL.

J Clin Oncol. 2015 Apr 1;33(10):1157-64. doi: 10.1200/JCO.2014.58.0571. Epub 2015 Feb 23. Erratum in: J Clin Oncol. 2015 May 20;33(15):1715.

18.

Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia.

Zimdahl B, Ito T, Blevins A, Bajaj J, Konuma T, Weeks J, Koechlein CS, Kwon HY, Arami O, Rizzieri D, Broome HE, Chuah C, Oehler VG, Sasik R, Hardiman G, Reya T.

Nat Genet. 2014 Mar;46(3):245-52. doi: 10.1038/ng.2889. Epub 2014 Feb 2.

19.

Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice.

Oehler VG.

Hematology Am Soc Hematol Educ Program. 2013;2013:176-83. doi: 10.1182/asheducation-2013.1.176. Review.

PMID:
24319179
20.

MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitors.

Morris VA, Zhang A, Yang T, Stirewalt DL, Ramamurthy R, Meshinchi S, Oehler VG.

PLoS One. 2013 Sep 24;8(9):e75815. doi: 10.1371/journal.pone.0075815. eCollection 2013.

21.

The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia.

Pogosova-Agadjanyan EL, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, List AF, May JJ, Oehler VG, Petersdorf S, Pogosov GL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL.

PLoS One. 2013 Aug 14;8(8):e70812. doi: 10.1371/journal.pone.0070812. eCollection 2013.

22.

Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data.

Yeung KY, Gooley TA, Zhang A, Raftery AE, Radich JP, Oehler VG.

Bioinformatics. 2012 Mar 15;28(6):823-30. doi: 10.1093/bioinformatics/bts059. Epub 2012 Jan 31.

23.

The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells.

Kim YM, Ma H, Oehler VG, Gang EJ, Nguyen C, Masiello D, Liu H, Zhao Y, Radich J, Kahn M.

Curr Cancer Drug Targets. 2011 Feb;11(2):213-25.

PMID:
21158719
24.

Regulation of myeloid leukaemia by the cell-fate determinant Musashi.

Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, Oehler VG, Radich JP, Jordan CT, Reya T.

Nature. 2010 Aug 5;466(7307):765-8. doi: 10.1038/nature09171. Epub 2010 Jul 18.

25.

The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data.

Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE, Radich JP.

Blood. 2009 Oct 8;114(15):3292-8. doi: 10.1182/blood-2009-03-212969. Epub 2009 Aug 4.

26.

The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.

Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley T, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E, Ladne P, Stirewalt DL, Abkowitz JL, Radich JP.

Blood. 2009 Oct 8;114(15):3299-308. doi: 10.1182/blood-2008-07-170282. Epub 2009 Jul 22.

27.

Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.

Oehler VG, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, Radich JP.

Leukemia. 2009 Feb;23(2):396-9. doi: 10.1038/leu.2008.183. Epub 2008 Jul 10. No abstract available.

28.

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.

Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cummings CC, Chu S, Bhatia R, Forman SJ, Negrin RS, Appelbaum FR, Radich JP.

Blood. 2007 Feb 15;109(4):1782-9. Epub 2006 Oct 24.

29.

Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.

Oehler VG, Radich JP.

Curr Hematol Malig Rep. 2006 Sep;1(3):152-9. doi: 10.1007/s11899-996-0003-x. Review.

PMID:
20425346
30.

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia.

Oehler VG, Radich JP, Storer B, Blume KG, Chauncey T, Clift R, Snyder DS, Forman SJ, Flowers ME, Martin P, Guthrie KA, Negrin RS, Appelbaum FR, Bensinger W.

Biol Blood Marrow Transplant. 2005 Feb;11(2):85-92.

31.

Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.

Oehler VG, Radich JP.

Curr Oncol Rep. 2003 Sep;5(5):426-35. Review.

PMID:
12895396

Supplemental Content

Loading ...
Support Center